SCHEMBL70443

SCHEMBL70443

CCCCCCc1cc(O)cc(O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 5/20 1.00
▸ CYP3A4 P08684 2/20 0.95
▸ ESR1 P03372 2/20 0.63
▸ ADRA2A P08913 2/20 0.63
▸ ADORA3 P0DMS8 2/20 0.63
▸ TACR2 P21452 2/20 0.63
▸ SLC6A2 P23975 2/20 0.63
▸ SLC6A4 P31645 2/20 0.63
▸ SLC6A3 Q01959 2/20 0.63
▸ KDM4E B2RXH2 1/20 0.63
▸ ALDH1A1 P00352 1/20 0.63
▸ LMNA P02545 1/20 0.63
▸ SHBG P04278 1/20 0.63
▸ TP53 P04637 1/20 0.63
▸ HSPD1 P10809 1/20 0.63
▸ ADRB3 P13945 1/20 0.63
▸ HTR2C P28335 1/20 0.63
▸ HSPE1 P61604 1/20 0.63
▸ HIF1A Q16665 1/20 0.63
▸ TST Q16762 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2468227 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL16432840 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3
Cardol SCHEMBL406402 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL4448056 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL68692 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL70292 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL70057 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL11737365 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL4444098 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL17201654 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230029027-A1 COMPOSITIONS AND METHODS FOR USING GENETICALLY MODIFIED ENZYMES RENEW BIOPHARMA, INC. 2023-01-26 — — US claimed
WO-2020210810-A9 COMPOSITIONS AND METHODS FOR USING GENETICALLY MODIFIED ENZYMES RENEW BIOPHARMA, INC. (US) 2020-11-26 — — WO claimed
WO-2020210810-A1 COMPOSITIONS AND METHODS FOR USING GENETICALLY MODIFIED ENZYMES RENEW BIOPHARMA, INC. (US) 2020-10-15 — — WO claimed
WO-2019183152-A1 COMPOSITIONS AND METHODS FOR USING GENETICALLY MODIFIED ENZYMES RENEW BIOPHARMA, INC. (US) 2019-09-26 — — WO claimed
EP-2087022-A1 MODIFIED ALKYLRESORCINOL RESINS AND APPLICATIONS THEREOF INDSPEC CHEMICAL CORPORATION (US) 2009-08-12 — — EP claimed
WO-2008048839-A1 MODIFIED ALKYLRESORCINOL RESINS AND APPLICATIONS THEREOF INDSPEC CHEMICAL CORPORATION (US) 2008-04-24 — — WO claimed
EP-1581579-A1 METHOD OF POLYCARBONATE PREPARATION GENERAL ELECTRIC COMPANY (US) 2005-10-05 — — EP claimed
US-6870025-B2 Method of polycarbonate preparation GENERAL ELECTRIC COMPANY (US) 2005-03-22 — — US claimed
WO-2004060962-A1 METHOD OF POLYCARBONATE PREPARATION GENERAL ELECTRIC COMPANY (US) 2004-07-22 — — WO claimed
US-20030149223-A1 Method of polycarbonate preparation GENERAL ELECTRIC COMPANY 2003-08-07 — — US claimed
EP-4714444-A1 PREPARATION FOR AND USE OF CANNABIDIOL DERIVATIVE DRUGS Changchun Institute Of Applied Chemistry Chinese Academy Of Sciences (CN) 2026-03-25 — — EP disclosed
US-12540315-B2 Compositions and methods for using genetically modified enzymes RENEW BIOPHARMA, INC. (US) 2026-02-03 — — US disclosed
WO-2024239921-A1 PREPARATION FOR AND USE OF CANNABIDIOL DERIVATIVE DRUGS 中国科学院长春应用化学研究所 2024-11-28 — — WO disclosed
US-20240117388-A1 ACYL ACTIVATING ENZYMES FOR PREPARATION OF CANNABINOIDS BAYMEDICA, INC. 2024-04-11 — — US disclosed
EP-4281553-A1 ACYL ACTIVATING ENZYMES FOR PREPARATION OF CANNABINOIDS BayMedica, Inc. (US) 2023-11-29 — — EP disclosed
US-20020066526-A1 Joint to be adhered to nylon resin moldings UBE INDUSTRIES, LTD. 2002-06-06 — — US disclosed
EP-1195419-A2 Joint for nylon resin moldings Ube Industries, Ltd. (JP) 2002-04-10 — — EP disclosed
US-5102972-A Noncrosslinked addition polymers of di ortho-substituted bismaleimides; fracture toughness; extension by noncatalytic Michael condensation ALLIED-SIGNAL INC. (US) 1992-04-07 — — US disclosed
US-4148809-A Process for preparing dl-cis-1-hydroxy-3-substituted-6,6-dimethyl-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-ones ELI LILLY AND COMPANY (US) 1979-04-10 — — US disclosed
US-3941812-A Thermally stable octanitro macrocyclic explosives THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) 1976-03-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12540315-B2 Compositions and methods for using genetically modified enzymes COASY, CYP4F3, CYP4F11 PTGS2 2841/4885CYP3A4 165/4885ESR1 1137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback